Saratov JOURNAL of Medical and Scientific Research
Home

Model for predicting metabolic syndrome in postmenopausal women

Year: 2025, volume 21 Issue: №2 Pages: 137-142
Heading: Obstetrics and Gynecology Article type: Original article
Authors: Danilova M.V., Usoltseva E.N., Vereina N.K., Nikushkina K.V., Pykhova L.R.
Organization: South Ural State Medical University
Summary:

Objective: to develop an effective prognostic model for the development of metabolic syndrome (MS) in women during early postmenopause. Material and methods. The case — control study included 82 early postmenopausal women. Group 1 consisted of 35 women with MS, group 2-47 women without MS. The research methods included the collection of medical history in a specially designed form, analysis of medical information from outpatient records, anthropometry and laboratory studies, assessment of the severity of menopausal syndrome by a modified menopausal index (MMI). Results. In patients with MS, compared with the control group, index HOMA-IR (Homeostasis Model Assessment of Insulin Resistance), the visceral adiposity index and MMI were significantly higher (p<0.001, p<0.001 and p=0.003, respectively), while the levels of follicle-stimulating hormone (p=0.008) and prolactin (p=0.011) were lower. Using the method of multiple logistic regression, a screening model has been developed to assess the likelihood of MS in women, including 5 parameters: somatic comorbidity, visceral adiposity index, MMI, levels of follicle-stimulating hormone and prolactin. The ROC curve was used to build the model. The area under the ROC curve (AUC) of the model was 0.909; 95% confidence interval 0.835-0.984 (sensitivity — 87.1 %, specificity — 78.6%). Conclusion. A prognostic model of the development of metabolic syndrome in women during early postmenopause has been developed, which helps identify patients with increased cardiometabolic risk, which will allow timely initiation of personalized preventive and treatment measures.

Keywords: menopausal metabolic syndrome, visceral adiposity index

Bibliography:
1. Kytikova OY, Antonyuk MV, Kantur ТА, et al. Prevalence and biomarkers in metabolic syndrome. Obesity and Metabolism. 2021;18(3):302-12. DOI:10.14341/omet12704
2. Hallajzadeh J, Khoramdad M, Izadi N, et al. Metabolic syndrome and its components in premenopausal and post-menopausal women: A comprehensive systematic review and meta-analysis on observational studies. Menopause. 2018;25 (10):1155. DOI:10.1097/GME.0000000000001136
3. Ebtekar F, Dalvand S, Gheshlagh RG. The prevalence of metabolic syndrome in postmenopausal women: A systematic review and meta-analysis in Iran. Diabetes Metab Syndr. 2018; 12 (6):955-60. DOI: 10.1016/j.dsx.2018.06.002
4. Pu D, Tan R, Yu Q, et al. Metabolic syndrome in menopause and associated factors: A meta-analysis. Climacteric. 2017;20(6):58391. DOI:10.1080/13697137.2017.1386649
5. Everson-Rose SA, Barinas-Mitchell EJM, El Khoudary SR, et al. Adipokines and subclinical cardiovascular disease in post-menopausal women: Study of women's health across the nation. J Am Heart Assoc. 2021;10(7):e019173. DOI:10.1161/JAHA.120.019173
6. Muka T, Oliver-Williams C, Colpani V, et al. Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease: A systematic review and meta-analysis. PLoS One. 2016;11(6):e0157417. DOI:10.1371/journal.pone.0157417
7. Armeni A, Anagnostis P, Armeni E, et al. Vasomotor symptoms and risk of cardiovascular disease in peri- and postmenopausal women: A systematic review and meta-analysis. Maturitas. 2023;171:13-20. DOI:10.1016/j.maturitas.2023.02.004
8. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: Addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387. DOI:10.1097/gme.0b013e31824d8f40
9. Amato MC, Giordano C, Galia M, et al. Visceral adiposity index. Diabetes Care. 2010;33(4):920-2. DOI:10.2337/dc09-1825
10. Bijari M, Jangjoo S, Emami N, et al. The accuracy of visceral adiposity index for the screening of metabolic syndrome: A systematic review and meta-analysis. Int J Endocrinol. 2021 ;2021:6684627. DOM0.1155/2021 /6684627
11. Lazzer S, D'Alleva M, Isola M, et al. Cardiometabolic Index (CMI) and Visceral Adiposity Index (VAI) highlight a higher risk of metabolic syndrome in women with severe obesity. J Clin Med. 2023;12 (9):3055. DOI:10.3390/jcm12093055
12. Crandall CJ, Barrett-Connor E. Endogenous sex steroid levels and cardiovascular disease in relation to the menopause: A systematic review. Endocrinol Metab Clin North Am. 2013;42 (2):227-53. DOL10.1016/j.ecl.2013.02.003
13. Gulamhusein N, Miranda KT, Ahmed SB, etal. Measurements of postmenopausal serum estradiol levels and cardiovascular events: A systematic review. CJC Open. 2024;6(2 Part B): 347-54. DOI:10.1016/j.cjco.2023.11.010
14. Tepper PG, Randolph JF, McConnell DS, etal. Trajectory clustering of estradiol and follicle-stimulating hormone during the menopausal transition among women in the Study of Women's Health Across the Nation (SWAN). J Clin Endocrinol Metab. 2012;97(8):2872-80. DOI:10.1210/jc.2012-1422
15. Jung ES, Choi EK, Park BH, et al. Serum follicle-stimulating hormone levels are associated with cardiometabolic risk factors in post-menopausal Korean women. J Clin Med. 2020;9 (4):1161. DOI:10.3390/jcm9041161
16. Lee SW, Hwang IS, Jung G, et al. Relationship between metabolic syndrome and follicle-stimulating hormone in postmenopausal women. Medicine (Baltimore). 2022;101 (18):e29216. DOI:10.1097/MD.0000000000029216
17. Chen Y, Wang C, Sun B, et al. Associations of follicle-stimulating hormone and luteinizing hormone with metabolic syndrome during the menopausal transition from the National Health and Nutrition Examination Survey. Front Endocrinol (Lausanne). 2023;14:1034934. DOI:10.3389/fendo.2023.1034934
18. Zhang C, Zhao M, Li Z, et al. Follicle-stimulating hormone positively associates with metabolic factors in peri-menopausal women. Int J Endocrinol. 2020;2020:7024321. DOI:10.1155/2020/7024321
19. Macotela Y, Ruiz-Herrera X, Vazquez-Carrillo Dl, et al. The beneficial metabolic actions of prolactin. Front Endocrinol (Lausanne). 2022;13:1001703. DOI:10.3389/fendo. 2022.1001703
20. Zaidalkilani AT, Al-Kuraishy HM, Al-Gareeb Al, et al. The beneficial and detrimental effects of prolactin hormone on metabolic syndrome: A double-edge sword. J Cell Mol Med. 2024;28 (23):e70067. DOI:10.1111/jcmm.70067

AttachmentSize
2025_02_137-142.pdf434.63 KB
All articles of the authors: Danilova M.V., Nikushkina K.V., Pykhova L.R. , Usoltseva E.N., Vereina N.K.

No votes yet